Lonza expands cell and gene therapy portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
The facility has been classified as Voluntary Action Indicated
Alembic receives EIR from USFDA for facility at Panelav
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The U.S. FDA issued a Form 483 with five observations
Subscribe To Our Newsletter & Stay Updated